Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey

Table 5 Induction and maintenance agents used by respondents^a

Indication	Agent	Respondents (%)
Induction agent in severe disease^b	Cyclophosphamide	66
	Rituximab	31
	Other	2
Induction agent if not using CYC or RTX (e.g. for less severe disease)^c	Methotrexate	40
	Azathioprine	30
	Mycophenolate	25
	Other	4
Maintenance therapy^d	Azathioprine	45
	Methotrexate	23
	Mycophenolate	18
	Rituximab	11
	Other	3

^aData represent percentage of respondents out of ^b n = 140, ^c n = 138, ^d n = 141

ISSN: 1546-0096